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Vascular Endothelial Growth Factor-A in Carotid
Atherosclerotic Plaques
A. Migdalski,1* M. Kotschy2 and A. Jawien1Departments of 1Surgery, and 2Pathophysiology, L. Rydygier Medical University, Bydgoszcz, PolandObjective. To determine the concentration of tissue factor (TF), tissue factor pathway inhibitor (TFPI) and vascular
endothelial growth factor A (VEGF-A) in carotid plaques.
Materials and methods. Thirty-eight consecutive patients (20 symptomatic, 18 asymptomatic) undergoing carotid
endarterectomy were enrolled into the current study. The concentration of TF, TFPI and VEGF-A in carotid plaque
homogenates and blood plasma was measured using enzyme immunoassay.
Results. The concentration of TF in carotid plaque homogenates was 60 fold higher than in blood plasma. There were no
statistically significant differences between the concentration of TF, TFPI and VEGF-A in symptomatic and asymptomatic
plaques. Carotid plaques of diabetic patients contained an increased level of TF and VEGF-A (pZ0.002, pZ0.005). The
plaque concentration of VEGF-Awas elevated among older patients (pZ0.02). Carotid plaques of non-smokers contained an
increased level of TFPI (pZ0.03). The concentration of TF, TFPI and VEGF-A in carotid plaques correlated positively with
plasma level of these factors (RZ0.86; p!0.0001; RZ0.91; p!0.0001; RZ0.80; pZ0.001, respectively). A highly positive
correlation between concentration of VEGF-A and TF, TFPI in carotid plaques was also observed (RZ0.75; p!0.001; RZ
0.62; p!0.001, respectively).
Conclusions. TF, TFPI and VEGF-A concentrations do not differ in atheroma removed from symptomatic and
asymptomatic patients but are higher in diabetic patients. There is a highly positive correlation between the level of VEGF-A
and TF, TFPI in carotid plaques.Keywords: Arteriosclerosis; Carotid stenosis; Blood coagulation factors; Endothelial growth factors.Introduction
Molecular mechanisms underlying atherosclerotic
plaque instability are incompletely understood. The
central event of the haemostatic process is the
generation of thrombin through the tissue factor (TF)
pathway. Tissue factor after interaction with plasma
factor VII at the site of vessel injury activates factor X
and IX, leading to thrombin generation. Within
atherosclerotic plaques, TF is expressed by vascular
smooth muscle cells (VSMCs), monocytes, macro-
phages and endothelial cells.1 Increased expression
of TF has been found in atherosclerotic plaques from
patients with unstable angina and myocardial infarc-
tion.2 It has been also demonstrated in a rabbit model
that atherosclerotic plaque rupture is associated with
increased TF production from circulating monocytes.3
TF overexpression in rat arterial neointima maying author. A. Migdalski, MD, Department of Surgery,
orial Hospital, Ujejskiego 75, 85-168 Bydgoszcz, Poland.
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dependent and -independent mechanisms and pro-
voke progression of advanced atherosclerosis through
its important role in neointimal formation.4 Tissue
factor is considered to be the principal molecule
linking plaque inflammation with arterial thromboem-
bolism.5,6 Activating protease activated receptors
(PARs) on vascular cells TF may contribute to other,
non-haemostatic, biological processes.7,8
The main inhibitor of coagulation is tissue factor
pathway inhibitor (TFPI) which is believed to play a
crucial role in the regulation of the function of vascular
wall cells. TFPI is able to modulate cell proliferation.1
TFPI is mainly associated with the surface of endo-
thelium and may be a marker of endothelial cell
dysfunction.1 Recent reports suggest that TFPI may
attenuate thrombosis and prevent restenosis. The
process of neovascularisation is thought to be respon-
sible for atherosclerotic plaque destabilization and
acceleration of plaque growth through episodes of
intraplaque microhemorrhages. Vascular endothelialEur J Vasc Endovasc Surg 30, 41–47 (2005)
doi:10.1016/j.ejvs.2005.02.055, available online at http://www.sciencedirect.com onved.
A. Migdalski et al.42growth factor-A (VEGF-A) is crucially involved in the
process of angiogenesis9–13 and, therefore, its concen-
tration in the ‘active’, destabilized carotid plaque is
speculated to be closely connected with TF and TFPI
plaque levels. It has been reported that immature
vessels formed during neovascularisation inside
atherosclerotic plaque may be the most important
source of the inflammatory focus.14
In our previous study, we have demonstrated that
the haemostatic profile of a symptomatic carotid
plaque differs from that of an asymptomatic plaque.15
Thrombin generation was significantly higher in
symptomatic carotid plaques (TAT).15 The haemostatic
composition of carotid plaque of patients with coex-
isting diabetes was also different (increased concen-
tration of thrombin–antithrombin complexes, tissue
plasminogen activator and D-dimers).15 It has been
also demonstrated that the carotid plaque of diabetic
patients differs with respect to content of selected
markers of endothelial activity (thrombomodulin,
endothelin, E-selectin, P-selectin).16
In this project we investigate the concentrations of
tissue factor (TF), tissue factor pathway inhibitor
(TFPI) and vascular endothelial growth factor A
(VEGF-A) in frozen samples of carotid atherosclerotic
plaques. The aim of the present study was to
determine the correlation between levels of tested
factors (TF, TFPI, VEGF-A) in carotid plaques and
blood plasma.Material and Methods
Frozen carotid plaques of 38 patients undergoing
carotid endarterectomy in the Department of Surgery
were used to perform the study. Complete medical
history of all patients was available, and the following
risk factors and coexisting diseases were recorded: sex,
age, body weight, hyperlipidemia (total cholesterol,
LDL, HDL, triglyceride), smoking status (1, never
smoked; 2, former smokers—quit O1 year; 3, current
smoker), peripheral arterial occlusive disease (ABPI!
0.9), hypertension (under hypotensive therapy or
blood pressure R160/95 mmHg), coronary artery
disease (angina pectoris, myocardial infarction, coron-
ary artery bypass grafting procedure or PTCA) and
diabetes (patients on diet, oral hypoglycemic agents,
insulin or with fasting glucose levels O126 mg/dl).
Patients were defined as symptomatic if symptoms
occurred less then 6 months before enrollment. In all
patients, the neck arteries were investigated by color
duplex ultrasound (7.5-MHz linear transducer, ATL
HDI 3500). Four patients in which the carotid arteries
were difficult to visualise by duplex underwentEur J Vasc Endovasc Surg Vol 30, July 2005angiography. The carotid stenosis was evaluated
using widely accepted diagnostic criteria for the
classification of carotid artery disease using mainly
velocity measurements.17 A peak systolic velocity
(PSV) of R125 cm/s was the threshold for the
diagnosis of a stenosis graded R50%. Higher-degree
stenoses were graded in categories of 5%, taking into
account the peak systolic velocity (PSV) and end
diastolic velocity in the jet of the stenosis, the peak
systolic velocity in the most distal poststenotic ICA,
spectral broadening and ICA/CCA PSV ratio. When
the ICA PSV wasR230 cm/s a stenosis ofR70% was
diagnosed.Sample preparation
Carotid plaques removed during endarterectomy
were washed carefully in saline and stored dry in the
freezer (at K20 8C). Venous blood samples (15 ml)
were collected in the fasting state before the operation
(8 a.m.). The blood was collected into a plastic
centrifugation-tube containing 3.8% natrium citrate
solution (1:10 proportion). Blood samples were cen-
trifuged immediately after sampling in order to obtain
platelet-free plasma (3000/min; 15 min). Platelet-free
plasma samples were stored at K20 8C. The concen-
tration of tissue factor, TFPI and VEGF-A in hom-
ogenates was tested in the laboratory of Department of
Pathophysiology using enzyme immunoassay
(ELISA). The concentration of TF, TFPI and VEGF-A
in carotid plaques was calculated per milligram
protein of homogenates. The measurement of the
concentration of tested factors in plasma enabled the
evaluation of correlation between concentration of
individual factors in carotid plaques and blood
plasma. Tests used in the present study:1. TF: IMUBIND Tissue Factor ELISA Kit American
Diagnostica Inc.2. TFPI: IMUBIND Total TFPI ELISA Kit American
Diagnostica Inc.3. VEGF-A: human VEGF-A BioLISA MedSystems
Diagnostics GmbH.4. Protein: Bis-cinchonian acid test (BCA).
Tests sensitivities are, respectively: TF (10 pg/ml);
TFPI (0.36 ng/ml); VEGF-A (11.0 pg/ml).Statistical analysis
Normal distribution of data was determined by the
Shapiro–Wilk normality test. The relationship between
risk factors of arteriosclerosis, symptomatic and
TF-TFPI-VEGF-A in Carotid Plaques 43asymptomatic carotid stenosis and the concentration
of tested factors in carotid plaques was examined
using the Mann–Whitney test. Student’s t-test was
used for comparison of two groups of values with
normal distribution. Correlation was calculated
according to Pearson. The Chi-squared test with
Yates modification was used for comparison of
differences in risk factors and coexisting disease
distribution. The criterion for statistical significance
was p!0.05.ResultsPatient demographics
Thirty-eight patients (26 men, 12 women, median age
67) were enrolled into the study. Twenty subjects had
symptomatic carotid stenosis and the other 18 patients
had no characteristic cerebral ischemic symptoms.
Most individuals were current and former smokers
(nZ33, 86.8%). Among 33 smokers, 18 (47.4%) were
current smokers and 15 (39.5%) stopped smoking
more than 1 year ago. Among all the patients enrolled
in the study 25 (65.8%) had hypertension and 7 (18.4%)
diabetes. Concomitant peripheral arterial occlusive
disease (PAOD) was found in 26 patients (68.4%).
Eighteen of these patients reported intermittent
claudication and eight individuals had no symptoms
of PAOD. Most of enrolled subjects were overweight
(nZ22) or obese (nZ11) (Table 1). The median carotid
stenosis severity was 75% overall (range 50–95%), 80%
for symptomatic patients (range, 50–95%) and 70% for
asymptomatic patients (range, 50–95%). None of
studied patients were on statins therapy prior toTable 1. Patient demographics and risk factors
Characteristic n (%)
Male 26 (68)
Symptomatic carotid stenosis 20 (51)
TIA 8 (21)
Stroke 13 (34)
Retinal embolism 3 (8)
Hypertension 25 (66)
CAD 17 (46)
Diabetes 7 (18)
PAOD 26 (68)
IC 18 (74)
Asymptomatic PAOD 8 (21)
Overweight (BMI 24.5–29) 22 (58)
Obesity (BMIO29) 11 (29)
Total cholesterolO200 mg/dl 19 (53)
TriglicerydesO200 mg/dl 6 (16)
Cholesterol LDLO100 mg/dl 26 (81)
Cholesterol HDL !40 mg/dl 17 (50)
PAOD, peripheral arterial occlusive disease; CAD, coronary artery
disease; IC, intermittent claudication.surgery. All of enrolled patients were on the aspirin
therapy (75 mg daily). There were no statistically
significant differences with respect to sex, age, risk
factors distribution and degree of stenosis between
symptomatic and asymptomatic patients.
There were increased mean concentrations of TF
and VEGF-A in carotid plaque homogenates in
comparison to plasma level of these factors. The
concentration of TF in carotid plaque homogenates
was almost 60 fold higher than in blood plasma. The
plasma TF level in study patients was within the
normal range and the mean plasma concentration of
VEGF was higher than normal (Table 2). A low
concentrations of TFPI in carotid plaques homogen-
ates was observed, 80 fold below the mean plasma
levels of TFPI (Table 2). There were no statistically
significant differences between concentration of TF,
TFPI and VEGF-A in carotid plaques of symptomatic
and asymptomatic patients (Table 3).
The influence of concomitant risk factors and
diseases on the level of TF, TFPI and VEGF-A in the
carotid plaque was evaluated. We demonstrated
increased concentrations of TF and VEGF-A in the
atheroma of diabetic patients (pZ0.002, pZ0.005,
respectively). There was also a trend toward increased
concentration of TFPI (pZ0.07) in carotid plaques of
diabetic patients but the difference did not reach
statistical significance. The small sample size likely
influenced the results (subgroup of diabetic patients
nZ7) (Table 4). There were no differences between
plasma concentration of TF, TFPI and VEGF-A in
diabetic and non-diabetic patients. The concentration
of VEGF-Awas elevated in the carotid plaques of older
patients (age R65, pZ0.02) (Table 5). Statistically
significant increased levels of TFPI in the carotid
plaque of non-smokers were demonstrated (pZ0.03)
(Table 5). There was no difference in the plaque
concentration of TF and VEGF-A in carotid plaque of
smokers and non-smokers. The composition of pre-
occlusive carotid plaques (R90% of stenosis) did not
differ from those with less advanced stenosis (Table 5).
There was no difference in the plaque concentration of
TF, TFPI and VEGF-A in hypertensive and normoten-
sive patients.Table 2. Concentration of TF, TFPI and VEGF-A in carotid plaque
homogenates and blood plasma of study patients
Parameters Carotid plaques Blood plasma
XGSD XGSD
TF (pg/ml) 7480G2350 130G80
TFPI (ng/ml) 5.0G3.3 400G240
VEGF-A (pg/ml) 1060G180 500G230
Reference data/normal plasma levels: TF (28–255 pg/ml), TFPI (75–
120 ng/ml), VEGF-A (75–140 pg/ml).
Eur J Vasc Endovasc Surg Vol 30, July 2005
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Eur J Vasc Endovasc Surg Vol 30, July 2005A highly positive correlation between concentration
of TF, TFPI and VEGF-A in the blood plasma and the
carotid plaque homogenates was found. The corre-
lation coefficients of Person (R) and p-values were,
respectively: TF (0.86/!0.0001); TFPI (0.91/!0.0001);
VEGF-A (0.80/0.001). A positive correlation between
the plaque concentration of VEGF-A and TF, TFPI was
also observed (Table 6).Discussion
The fibrous cap is the structure that separates the
blood stream from the necrotic core of the carotid
plaque.18 Fibrous cap rupture is believed to be the
main mechanism of carotid plaque destabilization and
embolization. It has been demonstrated that fibrous
cap rupture is more common in plaques with
increased inflammatory cells (macrophages and T-
cells).19 Plaque rupture exposes the necrotic core to the
blood stream and the TF pathway is activated. In the
healthy vessel wall TF is present only in the adventitia.
In atherosclerotic arteries TF is also present in the
intima. It has been demonstrated that there is a
significant positive association between TF expression
and intraplaque inflammatory cells content.20 In our
previous study we demonstrated that thrombinogen-
esis is increased in symptomatic carotid plaques15 and
we expected to find increased concentration of TF in
these plaques but surprisingly we have found no
difference between the concentration of TF in sympto-
matic and asymptomatic plaques. Jander et al. using
immunocytochemistry found a higher expression of
TF in symptomatic carotid plaques.20 Furthermore,
they demonstrated a highly significant association of
TF expression with the occurrence of cerebral micro-
embolism.20 In our present study the mean concen-
tration of TF and TFPI measured with the ELISA
technique in symptomatic and asymptomatic plaque
was similar. Themethodology differences between this
study and that of Jander and colleagues may explain
the disparate findings. There are also reports demon-
strating higher TF levels in atheroma from patients
with unstable angina compared with stable angina.21
Additional studies using TF are mandatory to clarify
its role in carotid plaque ‘activation’. Probably the
expression of TF (expressed by macrophage-derived
foam cells22) is higher only in some areas of sympto-
matic plaques were the number of inflammatory cells
is greatest.20
In healthy subjects TF antigen is present in the
plasma at a mean level of 149–172 pg/ml.23,24 Some
recent studies have shown that the levels of blood-
born TF are increased in atherosclerosis.25–27 Our
Table 4. The concentration of TF, TFPI and VEGF-A in carotid
plaques homogenates of diabetic and non-diabetic patients
Parameters All Non-diabetic
patients
Diabetic
patients
p*
XGSD XGSD XGSD
TF (pg/mg p) 2450G1280 2140G1150 3780G960 0.002
TFPI (ng/mg p) 1.7G1.4 1.6G1.4 2.3G1.1 0.07
VEGF-A
(ng/mg p)
350G140 310G140 470G70 0.005
* Mann–Whitney test.
TF-TFPI-VEGF-A in Carotid Plaques 45study has demonstrated that mean TF plasma concen-
tration in patients with advanced carotid atherosclero-
sis is within the normal range (mean 127G83 pg/ml)
but the mean TF concentration in carotid plaque
homogenates was almost 60 fold higher than in blood
plasma (mean 7478G2354 pg/ml) (Table 2).
Caplice et al. have demonstrated that TFPI is present
within human atherosclerotic plaques and may modu-
late plaque thrombogenicity by attenuating TF
activity.28 In Caplice study TFPI was undetectable in
30% of the plaque samples, suggesting that there may
be plaques relatively deficient in TFPI.28 In the present
study, we found TFPI in all tested carotid plaques. We
did not find statistically significant differences in TFPI
concentrations between symptomatic and asympto-
matic plaques. We did demonstrate increased level of
TFPI in the carotid plaques of non-smokers. Consider-
ing the potential active role of TFPI in the prevention
of thrombotic complications29,30 we assume thatTable 5. The concentration of TF, TFPI and VEGF-A in carotid plaq
diseases
TF TFPI
XGSD p* XGSD
R90% 1790G560 ns 0.6G0.4
!90% 2100G1160 1.8G1.6
CholR240 2460G1100 ns 1.2G1.3
Chol!240 2510G1370 1.9G1.4
LDLR130 2230G1300 ns 2.1G2.0
LDL!130 2740G1330 1.6G1.1
TGR200 2280G1100 ns 1.5G1.3
TG!200 2610G1410 1.9G1.5
BMIR29 2340G920 ns 2.0G1.5
BMI!29 2350G1420 1.6G1.4
Nikot.(C) 2420G1200 ns 1.1G0.9
Nikot.(K) 2470G1390 2.2G1.6
HA(C) 2350G1350 ns 1.9G1.5
HA(K) 2622G1170 1.3G1.1
IC(C) 2690G1420 ns 1.6G1.4
IC(K) 2220G1130 1.8G1.4
DM(C) 3780G960 0.002 2.3G1.1
DM(K) 2140G1150 1.6G1.4
AgeR65 2770G1510 0.07 2.1G1.6
Age!65 2030G750 1.3G1.0
HA, hypertension; IC, intermittent claudication; DM, diabetes; CholR
plasma levelR130 mg/dl; TGR200, plasma triglicerydes levelR200
smokers;R90%, ICA stenosisR90;!90%, ICA stenosis!90%; TF (p
* Mann–Whitney test.attenuated function of TFPI in smokers suffering
from advanced arteriosclerosis will predispose them
to a higher risk of thromboembolic complications.
We demonstrated in our earlier study that the most
marked changes in the carotid plaque haemostatic
composition was in diabetic patients (increased TAT, t-
PA and D-dimers level).15 In the present study, we
show that diabetic patients have increased level of TF
and VEGF-A in their carotid atheroma (Table 4). There
was also a trend towards increased concentration of
TFPI in the carotid plaques of diabetic patients (2.3 vs.
1.6 ng/mg p; pZ0.07) but the difference did not reach
statistical significance. Possibly the small sample size
influenced these results. The increased expression of
TF in type 2 diabetes mellitus correlated with
components of the metabolic syndrome has previously
been reported.31
The other important trigger mechanism of destabi-
lization and acceleration of an atherosclerotic plaque
growth is believed to be intraplaque microhemor-
rhage. Intraplaque neovascularization and hemor-
rhage may facilitate plaque progression. VEGF-A
acts on endothelial cells (stimulating endothelial
proliferation and migration) and monocytes which
participate in the angiogenic process.13,32 Small,
vulnerable vessels are formed during the neovascular-
ization process inside advanced atheroma. Such
vessels are particularly susceptible to rupture. During
the intraplaque microhemorrhage the coagulationues in relation to degree of stenosis, risk factors and coexisting
VEGF-A
p* XGSD p*
ns 250G100 ns
340G120
ns 320G120 ns
360G150
ns 320G120 ns
380G150
ns 289G140 ns
360G140
ns 360G130 ns
330G150
0.03 310G140 0.08
380G140
ns 350G150 ns
330G130
ns 380G140 ns
310G150
0.07 470G70 0.005
310G140
0.18 390G130 0.02
280G140
240, total plasma cholesterol levelR240 mg/dl; LDLR130, LDL
mg/dl; BMI, body mass index; Nikot.(C), smokers; Nikot.(K), non-
g/mg p); TFPI, VEGF-A (ng/mg p).
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Table 6. Correlations between concentrations of TF, TFPI, VEGF-A
and haemostatic factors in carotid plaques homogenates
TF TFPI VEGF-A
R/p R/p R/p
TF – 0.37/0.03 0.75/!0.001
TFPI 0.37/0.03 – 0.62/!0.001
VEGF-A 0.75/!0.001 0.62/!0.001 –
TF, tissue factor; TFPI, tissue factor pathway inhibitor; VEGF-A,
vascular endothelial growth factor A; R, correlation coefficient of
Pearson.
A. Migdalski et al.46process is activated. VEGF-A and its receptors are
crucially involved in process of angiogenesis9–13 and
we believed that VEGF-A could be a good marker of
neovascularisation activity. Therefore, we expected to
find increased concentration of VEGF-A inside symp-
tomatic carotid plaques. In our present study there
were no differences in VEGF-A concentration between
symptomatic and asymptomatic carotid plaque but we
did find statistically significant increased VEGF-A
level in carotid plaques of diabetic patients (Tables 3
and 4). This is an interesting finding in light of earlier
reports that specific and strong VEGF-A-induced
chemotactic response of monocytes are attenuated in
diabetic patients.33 It has been demonstrated by
Ferrara et al. that diabetic retinopathy is associated
with high intraocular levels of VEGF-A.34 It has been
also reported that TF may play an additional non
haemostatic role in blood vessel development.35 The
carotid plaques of diabetic patients in our study group
were characterized by increased concentration of TF
and VEGF-A (Table 4). These findings indicate not
only increased haemostatic activity but also greater
angiogenesis in these plaques. We assume that
neovascularisation, consecutive intraplaque microhe-
morrhages and TF pathway activation could be the
crucial processes determining the activity of diabetic
patients’ carotid plaques. An association of angiogenic
mediators with microvessels and with the severity of
atherosclerosis has recently been reported.36 Our
finding suggests that neovascularisation could be a
crucial mechanism responsible for more aggressive
progress of atherosclerosis in diabetic patients.
It has been reported that the normal median plasma
level of VEGF-A in healthy individuals is 98 pg/ml
(25th and 75th percentiles, 75 and 137 pg/ml).33 Our
study patients with advanced carotid atherosclerosis
had increased plasma level of VEGF-A (mean
504 pg/ml)(Table 2).
On the basis of our present and former studies15 we
assume that thrombin (as TAT complexes) but not TF
could be a good marker of ‘active’ carotid plaque. We
have found increased concentration of thrombin–
antithrombin complexes (TAT) in symptomatic carotid
plaques but the concentration of TF in these plaquesEur J Vasc Endovasc Surg Vol 30, July 2005was not elevated. That could means that thrombin
activation takes place through TF independent path-
ways, such as platelet-located activation of thrombin
by factor XI.37 The available data provides evidence
that thrombin signaling in vascular development
cannot be explained by a model based only on the
classic extrinsic and intrinsic coagulation pathways.38
Thrombin is one of the most potent stimuli for non-
hypoxic VEGF expression39 and also upregulates
VEGF receptors in endothelial cells40 which may
explain the effects of thrombin on angiogenesis and
vascular development.41 VEGF in turn accelerates
thrombin generation, suggesting that these two factors
act as part of a positive feedback loop to accelerate the
angiogenic process.42
We must underline the limitations of the present
study. The study would benefit from control samples of
the carotid wall (potentially free of athermanous
changes). We used ELISA tests for quantitative deter-
mination of concentration of TF, TFPI and VEGF-A in
carotid plaques homogenates. It is possible that the
expression of the tested factors is higher only in some
areas of carotid plaque. Using different techniques for
the calculation of expression of these factors in the
carotid plaques (ELISA, immunochemistry or Western
blotting) would further clarify this issue.Conclusions
Symptomatic and asymptomatic plaques do not differ
with respect to TF, TFPI and VEGF-A mean concen-
tration. The concentration of VEGF-A in carotid
plaques correlate positively with TF and TFPI levels.
Among risk factors of atherosclerosis diabetes exerts
the most marked influence on the concentration of TF
and VEGF-A in carotid plaques homogenates.References
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